Finding natural products to help eliminate HIV reservoirs
Development of natural product inhibitors of Nef for clearance of HIV reservoirs
This study is looking for natural substances that can block a protein in HIV called Nef, which helps the virus hide from the immune system, with the hope of making current treatments better for people living with HIV by helping their immune systems recognize and fight the virus more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10652446 on NIH RePORTER |
What this research studies
This research focuses on developing natural product inhibitors that target a specific HIV protein called Nef, which helps the virus evade the immune system. By inhibiting Nef, the goal is to enhance the effectiveness of existing treatments that reactivate latent HIV cells, allowing the immune system to recognize and eliminate these infected cells. The researchers are using advanced screening methods to identify potential inhibitors that can restore the immune response against HIV. This approach aims to create a more effective combination therapy for individuals living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have not achieved viral eradication despite ongoing antiretroviral therapy.
Not a fit: Patients who are not living with HIV or those who have not responded to any form of antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively eliminate hidden HIV reservoirs, potentially curing HIV infection.
How similar studies have performed: While the approach of targeting Nef is innovative, previous research has shown promise in similar strategies aimed at reactivating latent HIV, indicating potential for success.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Sherman, David H — University of Michigan at Ann Arbor
- Study coordinator: Sherman, David H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.